---
provider: openscientist
model: openscientist-autonomous
cached: false
start_time: '2026-09-05T07:07:42.415548'
end_time: '2026-09-05T07:26:32.237035'
duration_seconds: 1129.82
template_file: templates/disease_pathophysiology_research.md
template_sha: 1e7ea4ee817acfe1dda5f77fafe6f2e8b5927666
template_variables:
  disease_name: Noonan Syndrome 6
  mondo_id: MONDO:0013186
  category: Mendelian
provider_config:
  timeout: 3600
  max_retries: 3
  parameters:
    allowed_domains: []
    max_iterations: 5
    use_hypotheses: false
    investigation_mode: autonomous
    poll_interval: 30
    timeout: 3600
    save_artifacts: true
    artifact_max_bytes: 5242880
citation_count: 26
reference_validation:
  total_references: 26
  verified: 26
  not_found: 0
  unverifiable: 0
  confabulation_rate: 0.0
  relevance_assessed: 26
  on_topic: 13
  validator_version: 0.2.1
term_validation:
  total_terms: 28
  verified: 26
  not_found: 0
  obsolete: 0
  unverifiable: 2
  confabulation_rate: 0.0
  labels_checked: 21
  labels_matching: 2
  labels_mismatched: 15
  mislabelled_terms:
  - term_id: MONDO:0013186
    reported_labels:
    - if available
    - MONDO
    ontology_label: Noonan syndrome 6
  - term_id: HP:0001639
    reported_labels:
    - Physical/clinical sign
    ontology_label: Hypertrophic cardiomyopathy
  - term_id: HP:0004322
    reported_labels:
    - Physical
    ontology_label: Short stature
  - term_id: HP:0001999
    reported_labels:
    - Physical
    ontology_label: Abnormal facial shape
  - term_id: HP:0000465
    reported_labels:
    - Physical
    ontology_label: Webbed neck
  - term_id: HP:0001892
    reported_labels:
    - Lab/clinical
    ontology_label: Abnormal bleeding
  - term_id: HP:0000766
    reported_labels:
    - Physical
    ontology_label: Abnormal sternum morphology
  - term_id: HP:0000028
    reported_labels:
    - Clinical sign
    ontology_label: Cryptorchidism
  - term_id: HP:0002092
    reported_labels:
    - Clinical sign
    ontology_label: Pulmonary arterial hypertension
  - term_id: HP:0000112
    reported_labels:
    - Physical
    ontology_label: Nephropathy
  - term_id: HP:0000407
    reported_labels:
    - Clinical sign
    ontology_label: Sensorineural hearing impairment
  - term_id: NCIT:C2039
    reported_labels:
    - Beta-blockers / non-dihydropyridine CCBs
    ontology_label: Bevacizumab
  - term_id: NCIT:C51756
    reported_labels:
    - Septal myectomy / modified Konno
    ontology_label: Roux-en-Y Anastomosis
  - term_id: NCIT:C15380
    reported_labels:
    - Heart transplantation
    ontology_label: Telemedicine
  - term_id: NCIT:C1968
    reported_labels:
    - Recombinant growth hormone
    ontology_label: Topoisomerase-II Inhibitor
  labels_variant: 4
  unresolvable_prefixes:
  - ORPHA
  needs_review: true
  adapter: 'ols:'
  validator_version: 0.4.5
artifact_count: 2
artifact_sources:
  openscientist_artifacts_zip: 2
artifacts:
- filename: final_report.html
  path: Noonan_Syndrome_6-deep-research-openscientist_artifacts/final_report.html
  media_type: text/html
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
- filename: final_report.pdf
  path: Noonan_Syndrome_6-deep-research-openscientist_artifacts/final_report.pdf
  media_type: application/pdf
  source: openscientist_artifacts_zip
  data_storage_id: null
  description: OpenScientist final report
---

## Question

# Disease Characteristics Research Template

## Target Disease
- **Disease Name:** Noonan Syndrome 6
- **MONDO ID:** MONDO:0013186 (if available)
- **Category:** Mendelian

## Research Objectives

Please provide a comprehensive research report on **Noonan Syndrome 6** covering all of the
disease characteristics listed below. This report will be used to populate a disease knowledge
base entry. Be thorough and cite primary literature (PMID preferred) for all claims.

For each section, **suggested databases/resources** are listed. These are the first places
you should search for information on each topic.

---

### 1. Disease Information
> **Search first:** OMIM, Orphanet, ICD-10/ICD-11, MeSH, PubMed

- What is the disease? Provide a concise overview.
- What are the key identifiers? (OMIM, Orphanet, ICD-10/ICD-11, MeSH, Mondo)
- What are the common synonyms and alternative names?
- Is the information derived from individual patients (e.g., EHR) or aggregated disease-level resources?

### 2. Etiology

- **Disease Causal Factors**: What are the primary causes? (genetic, environmental, infectious, mechanistic)
- **Risk Factors**:
  > **Search first:** PubMed, Cochrane Library, UpToDate, clinical guidelines, ClinVar, ClinGen, GWAS Catalog, PheGenI, CTD, CDC, WHO, epidemiological databases
  - Genetic risk factors (causal variants, susceptibility loci, modifier genes)
  - Environmental risk factors (toxins, lifestyle, occupational exposures, age, sex, family history)
- **Protective Factors**:
  > **Search first:** PubMed, Cochrane Library, clinical trial databases, GWAS Catalog, gnomAD, WHO, CDC, nutrition databases
  - Genetic protective factors (protective variants, modifier alleles)
  - Environmental protective factors (diet, lifestyle, exposures that reduce risk)
- **Gene-Environment Interactions**: How do genetic and environmental factors interact to influence disease?
  > **Search first:** CTD, PubMed, PheGenI, GxE databases

### 3. Phenotypes
> **Search first:** HPO (Human Phenotype Ontology), OMIM, Orphanet, PubMed, clinicaltrials.gov, MedDRA, SNOMED CT, DECIPHER, LOINC

For each phenotype, provide:
- **Phenotype type**: symptoms, clinical signs, physical manifestations, behavioral changes, or laboratory abnormalities
  > For symptoms/signs: HPO, OMIM, Orphanet, PubMed
  > For behavioral changes: HPO, DSM, RDoC (Research Domain Criteria), PubMed
  > For laboratory abnormalities: LOINC, SNOMED CT, LabTests Online, PubMed
- **Phenotype characteristics**:
  > **Search first:** OMIM, Orphanet, HPO, PubMed
  - Age of symptom onset (neonatal, childhood, adult-onset, late-onset)
  - Symptom severity (mild, moderate, severe, variable)
  - Symptom progression (stable, progressive, episodic, fluctuating)
  - Frequency among affected individuals (percentage or qualitative)
- **Quality of life impact**: Effects on daily functioning and well-being (per-phenotype when possible)
  > **Search first:** EQ-5D database, SF-36, WHO QOL databases, PubMed
- Suggest HPO (Human Phenotype Ontology) terms for each phenotype

### 4. Genetic/Molecular Information

- **Causal Genes**: Gene mutations or chromosomal abnormalities responsible for disease (gene symbols, OMIM IDs)
  > **Search first:** OMIM, ClinVar, HGMD, Ensembl, NCBI Gene
- **Pathogenic Variants**:
  - Affected genes (gene symbols, HGNC IDs)
    > **Search first:** OMIM, NCBI Gene, Ensembl, HGNC, UniProt, GeneCards
  - Variant classification (pathogenic, likely pathogenic, VUS per ACMG/AMP guidelines)
    > **Search first:** ClinVar, ClinGen, ACMG/AMP guidelines, VarSome
  - Variant type/class (missense, frameshift, nonsense, splice-site, structural)
  - Allele frequency in population databases
    > **Search first:** gnomAD, 1000 Genomes, ExAC, TOPMed, dbSNP
  - Somatic vs germline origin
    > **Search first:** COSMIC (somatic), ClinVar, ICGC, TCGA
  - Functional consequences (loss of function, gain of function, dominant negative)
- **Modifier Genes**: Genes that modify disease severity or expression
- **Epigenetic Information**: DNA methylation, histone modifications, chromatin changes affecting disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Chromosomal Abnormalities**: Large-scale genetic changes (aneuploidy, translocations, inversions)
  > **Search first:** DECIPHER, ClinVar, ECARUCA, UCSC Genome Browser

### 5. Environmental Information

- **Environmental Factors**: Non-genetic contributing factors (toxins, radiation, pollution, occupational exposure)
  > **Search first:** CTD (Comparative Toxicogenomics Database), TOXNET, PubMed, EPA databases
- **Lifestyle Factors**: Behavioral factors (smoking, diet, exercise, alcohol consumption)
  > **Search first:** CDC databases, WHO, PubMed, NHANES
- **Infectious Agents**: If applicable, pathogens causing or triggering disease (bacteria, viruses, fungi, parasites)
  > **Search first:** NCBI Taxonomy, ViPR, BV-BRC, MicrobeDB, GIDEON

### 6. Mechanism / Pathophysiology

**Present this section as an ordered causal chain first, then the detail below.**
Open with a numbered sequence of mechanistic steps running from the initiating
lesion (mutation, exposure, infection) to the clinical manifestation, one step per
line, each naming what it causes next. State the causal verb explicitly ("leads
to", "results in") and say where a step is inferred rather than demonstrated.
Where the mechanism branches, show the branch. The categories below are a
checklist of what to cover within those steps, not the organizing structure —
a step may draw on several of them, and a category may contribute to several
steps.

- **Molecular Pathways**: Specific signaling cascades or biochemical pathways involved (Wnt, MAPK, mTOR, PI3K-AKT, etc.)
  > **Search first:** KEGG, Reactome, WikiPathways, PathBank, BioCyc
- **Cellular Processes**: Cell-level mechanisms (apoptosis, autophagy, cell cycle dysregulation, inflammation, etc.)
  > **Search first:** Gene Ontology (GO), Reactome, KEGG, PubMed
- **Protein Dysfunction**: How protein structure or function is altered (misfolding, aggregation, loss of function, gain of function)
  > **Search first:** UniProt, PDB (Protein Data Bank), InterPro, Pfam, AlphaFold
- **Metabolic Changes**: Alterations in metabolic processes (energy metabolism, lipid metabolism, amino acid metabolism)
  > **Search first:** KEGG, BioCyc, HMDB (Human Metabolome Database), BRENDA
- **Immune System Involvement**: Role of immune response (autoimmunity, immunodeficiency, chronic inflammation)
  > **Search first:** ImmPort, Immunome Database, IEDB, Gene Ontology
- **Tissue Damage Mechanisms**: How tissues/ are injured (oxidative stress, ischemia, fibrosis, necrosis)
  > **Search first:** PubMed, Gene Ontology, Reactome
- **Biochemical Abnormalities**: Specific molecular defects (enzyme deficiencies, receptor dysfunction, ion channel defects)
  > **Search first:** BRENDA, UniProt, KEGG, OMIM, PubMed
- **Epigenetic Changes**: DNA methylation, histone modifications affecting gene expression in disease
  > **Search first:** ENCODE, Roadmap Epigenomics, MethBase, DiseaseMeth
- **Molecular Profiling** (if available):
  - Transcriptomics/gene expression changes
    > **Search first:** GEO (Gene Expression Omnibus), ArrayExpress, GTEx, Human Cell Atlas, SRA
  - Proteomics findings
    > **Search first:** PRIDE, ProteomeXchange, Human Protein Atlas, STRING, BioGRID
  - Metabolomics signatures
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB, METLIN
  - Lipidomics alterations
    > **Search first:** LIPID MAPS, SwissLipids, LipidHome, Metabolomics Workbench
  - Genomic structural features
    > **Search first:** UCSC Genome Browser, Ensembl, NCBI, dbVar, DGV
- **Advanced Technologies** (if applicable):
  - Single-cell analysis findings (cell-type specific mechanisms, cellular heterogeneity)
    > **Search first:** Human Cell Atlas, Single Cell Portal, GEO, CELLxGENE
  - Spatial transcriptomics findings
    > **Search first:** GEO, Spatial Research, Vizgen, 10x Genomics data
  - Multi-omics integration results
    > **Search first:** TCGA, ICGC, cBioPortal, LinkedOmics, PubMed
  - Functional genomics screens (CRISPR, RNAi)
    > **Search first:** DepMap, GenomeRNAi, PubMed, BioGRID ORCS

For each mechanism, describe:
- The causal chain from initial trigger to clinical manifestation
- Which mechanisms are upstream vs downstream
- What cell types and biological processes are involved
- Suggest GO terms for biological processes and CL terms for cell types

### 7. Anatomical Structures Affected

- **Organ Level**:
  - Primary organs directly affected
  - Secondary organ involvement (complications, secondary effects)
  - Body systems involved (cardiovascular, nervous, digestive, respiratory, endocrine, etc.)
  > **Search first:** Uberon, FMA (Foundational Model of Anatomy), OMIM, HPO, ICD-11, MeSH, SNOMED CT
- **Tissue and Cell Level**:
  - Specific tissue types affected (epithelial, connective, muscle, nervous)
  - Specific cell populations targeted (with Cell Ontology terms)
  > **Search first:** Uberon, Human Protein Atlas, Cell Ontology, Human Cell Atlas, CellMarker, PanglaoDB
- **Subcellular Level**:
  - Cellular compartments involved (mitochondria, nucleus, ER, lysosomes) (with GO Cellular Component terms)
  > **Search first:** Gene Ontology (Cellular Component), UniProt, Human Protein Atlas
- **Localization**:
  - Specific anatomical sites (with UBERON terms)
    > **Search first:** FMA, Uberon, NeuroNames (for brain), SNOMED CT
  - Lateralization (unilateral, bilateral, asymmetric)
    > **Search first:** HPO, clinical literature, imaging databases

### 8. Temporal Development

- **Onset**:
  - Typical age of onset (congenital, pediatric, adult, geriatric)
  - Onset pattern (acute, subacute, chronic, insidious)
  > **Search first:** OMIM, Orphanet, HPO, PubMed
- **Progression**:
  - Disease stages (early, intermediate, advanced, end-stage)
    > **Search first:** Cancer Staging Manual (AJCC), WHO classifications, PubMed
  - Progression rate (rapid, slow, variable)
  - Disease course pattern (episodic, relapsing-remitting, progressive, stable)
  - Disease duration (self-limited, chronic lifelong)
  > **Search first:** Disease registries, longitudinal cohort databases, natural history studies, PubMed, Orphanet, OMIM
- **Patterns**:
  - Remission patterns (spontaneous, treatment-induced)
    > **Search first:** Clinical trial databases, disease registries, PubMed
  - Critical periods (time windows of vulnerability or opportunity for intervention)
    > **Search first:** PubMed, developmental biology databases, clinical guidelines

### 9. Inheritance and Population

- **Epidemiology**:
  - Prevalence (cases per 100,000 at given time)
  - Incidence (new cases per 100,000 per year)
  > **Search first:** Orphanet, CDC, WHO, GBD (Global Burden of Disease), national registries, SEER, disease registries
- **For Genetic Etiology**:
  - Inheritance pattern (AD, AR, X-linked, mitochondrial, multifactorial, polygenic)
    > **Search first:** OMIM, Orphanet, ClinVar, GTR (Genetic Testing Registry)
  - Penetrance (complete, incomplete, age-dependent)
    > **Search first:** ClinVar, OMIM, PubMed, ClinGen
  - Expressivity (variable, consistent)
    > **Search first:** OMIM, ClinVar, PubMed
  - Genetic anticipation (increasing severity in successive generations)
    > **Search first:** OMIM, PubMed (especially for repeat expansion disorders)
  - Germline mosaicism
    > **Search first:** ClinVar, OMIM, genetic counseling literature, PubMed
  - Founder effects (population-specific mutations)
    > **Search first:** gnomAD, population genetics databases, PubMed
  - Consanguinity role
    > **Search first:** OMIM, population studies, genetic counseling resources
  - Carrier frequency
    > **Search first:** gnomAD, carrier screening databases, GeneReviews, GTR
- **Population Demographics**:
  - Affected populations (ethnic or demographic groups with higher prevalence)
    > **Search first:** gnomAD, 1000 Genomes, PAGE Study, PubMed, population registries
  - Geographic distribution (endemic areas, regional variation)
    > **Search first:** WHO, CDC, GBD, Orphanet, geographic epidemiology databases
  - Geographic distribution of specific variants
  - Sex ratio (male:female)
    > **Search first:** Disease registries, OMIM, PubMed, epidemiological databases
  - Age distribution of affected individuals
    > **Search first:** CDC, disease registries, SEER, Orphanet

### 10. Diagnostics

- **Clinical Tests**:
  - Laboratory tests (blood, urine, tissue chemistry, specific enzyme assays)
    > **Search first:** LOINC, LabTests Online, PubMed
  - Biomarkers (proteins, metabolites, genetic markers, circulating biomarkers)
    > **Search first:** FDA Biomarker List, BEST (Biomarkers, EndpointS, and other Tools), PubMed
  - Imaging studies (X-ray, CT, MRI, PET, ultrasound)
    > **Search first:** RadLex, DICOM, Radiopaedia, imaging databases
  - Functional tests (pulmonary function, cardiac stress tests)
    > **Search first:** LOINC, clinical guidelines, PubMed
  - Electrophysiology (EEG, EMG, ECG, nerve conduction studies)
    > **Search first:** LOINC, clinical neurophysiology databases, PubMed
  - Biopsy findings (histopathology, immunohistochemistry)
    > **Search first:** SNOMED CT, College of American Pathologists resources, PubMed
  - Pathology findings (microscopic examination)
    > **Search first:** SNOMED CT, Digital Pathology databases, PubMed
- **Genetic Testing**:
  > **Search first:** GTR (Genetic Testing Registry), GeneReviews, ClinGen
  - Overview of recommended genetic testing approach
  - Whole genome sequencing (WGS) utility
    > **Search first:** GTR, ClinVar, GEL (Genomics England), gnomAD
  - Whole exome sequencing (WES) utility
    > **Search first:** GTR, ClinVar, OMIM, GeneMatcher
  - Gene panels (which panels, which genes)
    > **Search first:** GTR, ClinVar, laboratory-specific databases
  - Single gene testing
    > **Search first:** GTR, ClinVar, OMIM, GeneReviews
  - Chromosomal microarray (CMA)
    > **Search first:** DECIPHER, ClinVar, dbVar, ECARUCA
  - Karyotyping
    > **Search first:** Chromosome Abnormality Database, ClinVar, cytogenetics resources
  - FISH
    > **Search first:** ClinVar, cytogenetics databases, PubMed
  - Mitochondrial DNA testing
    > **Search first:** MITOMAP, MSeqDR, ClinVar, GTR
  - Repeat expansion testing
    > **Search first:** GTR, ClinVar, repeat expansion databases, PubMed
- **Omics-Based Diagnostics** (if applicable):
  - RNA sequencing / transcriptomics
    > **Search first:** GEO, ArrayExpress, GTEx, RNA-seq databases
  - Proteomics
    > **Search first:** PRIDE, ProteomeXchange, FDA Biomarker database
  - Metabolomics
    > **Search first:** MetaboLights, Metabolomics Workbench, HMDB
  - Epigenomics
    > **Search first:** GEO, ENCODE, Roadmap Epigenomics, MethBase
  - Liquid biopsy
    > **Search first:** COSMIC, ClinVar, liquid biopsy databases, PubMed
- **Clinical Criteria**:
  - Standardized diagnostic criteria (DSM, ICD, society guidelines)
    > **Search first:** DSM-5, ICD-11, clinical society guidelines, UpToDate
  - Differential diagnosis (other conditions to rule out, with distinguishing features)
    > **Search first:** DynaMed, UpToDate, clinical decision support systems
- **Screening**:
  - Screening methods for asymptomatic individuals (newborn screening, carrier screening, cascade screening)
    > **Search first:** ACMG recommendations, CDC newborn screening, GTR

### 11. Outcome/Prognosis

- **Survival and Mortality**:
  - Survival rate (5-year, 10-year, overall)
    > **Search first:** SEER, cancer registries, disease-specific registries, PubMed
  - Life expectancy (with and without treatment if applicable)
    > **Search first:** Orphanet, disease registries, actuarial databases, PubMed
  - Mortality rate
    > **Search first:** CDC, WHO, GBD, national mortality databases
  - Disease-specific mortality (deaths directly attributable to disease)
    > **Search first:** Disease registries, CDC Wonder, GBD, PubMed
- **Morbidity and Function**:
  - Morbidity (disease-related disability and health impacts)
    > **Search first:** GBD, WHO, disability databases, PubMed
  - Disability outcomes (long-term functional impairments)
    > **Search first:** ICF (International Classification of Functioning), disability registries
  - Quality of life measures (EQ-5D, SF-36, PROMIS, disease-specific tools)
    > **Search first:** EQ-5D database, SF-36, PROMIS, PubMed
- **Disease Course**:
  - Complications (secondary problems: infections, organ failure, etc.)
    > **Search first:** ICD codes, disease registries, clinical databases, PubMed
  - Recovery potential (likelihood and extent of recovery, with vs without treatment)
    > **Search first:** Natural history studies, rehabilitation databases, PubMed
- **Prediction**:
  - Prognostic factors (age, disease severity, biomarkers, treatment response)
    > **Search first:** Prognostic models databases, clinical calculators, PubMed
  - Prognostic biomarkers (molecular markers predicting disease course)
    > **Search first:** FDA Biomarker database, PubMed, cancer prognostic databases

### 12. Treatment

- **Pharmacotherapy**:
  - Pharmacological treatments (drug names, drug classes, mechanisms of action)
    > **Search first:** DrugBank, RxNorm, ATC classification, DailyMed, FDA databases
  - Pharmacogenomics (how genetic variants affect drug metabolism, efficacy, toxicity)
    > **Search first:** PharmGKB, CPIC (Clinical Pharmacogenetics), FDA Table of PGx Biomarkers
- **Advanced Therapeutics**:
  - Gene therapy (viral vectors, CRISPR, gene replacement, gene editing)
    > **Search first:** ClinicalTrials.gov, FDA gene therapy database, ASGCT resources
  - Cell therapy (stem cell transplant, CAR-T, cellular therapeutics)
    > **Search first:** ClinicalTrials.gov, FDA cell therapy database, FACT standards
  - RNA-based therapies (ASOs, siRNA, mRNA therapies)
    > **Search first:** ClinicalTrials.gov, FDA approvals, PubMed
  - Targeted therapies (treatments directed at specific molecular targets)
    > **Search first:** My Cancer Genome, OncoKB, ClinicalTrials.gov, FDA approvals
  - Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
    > **Search first:** Cancer Immunotherapy Database, FDA approvals, ClinicalTrials.gov
- **Surgical and Interventional**:
  - Surgical interventions (types of surgery, timing, outcomes)
    > **Search first:** CPT codes, surgical registries, clinical guidelines, PubMed
- **Supportive and Rehabilitative**:
  - Supportive care (symptom management, pain control, nutrition)
    > **Search first:** Clinical guidelines, Cochrane Library, PubMed
  - Rehabilitation (physical therapy, occupational therapy, speech therapy)
    > **Search first:** Rehabilitation medicine databases, clinical guidelines, PubMed
- **Experimental**:
  - Experimental treatments in clinical trials (with NCT identifiers if available)
    > **Search first:** ClinicalTrials.gov, EU Clinical Trials Register, WHO ICTRP
- **Treatment Outcomes**:
  - Treatment response rates
    > **Search first:** Clinical trial databases, FDA reviews, systematic reviews, PubMed
  - Side effects and adverse events
    > **Search first:** FDA Adverse Event Reporting System (FAERS), MedWatch, PubMed
- **Treatment Strategy**:
  - Treatment algorithms (clinical pathways, decision trees)
    > **Search first:** Clinical practice guidelines, NCCN Guidelines, UpToDate
  - Combination therapies
    > **Search first:** ClinicalTrials.gov, treatment guidelines, PubMed
  - Personalized medicine approaches (genotype-guided treatment)
    > **Search first:** My Cancer Genome, CIViC, PharmGKB, precision medicine databases

For each treatment, suggest NCIT (NCI Thesaurus) clinical-intervention terms where applicable.

### 13. Prevention

- **Prevention Levels**:
  - Primary prevention (preventing disease occurrence: vaccination, risk factor modification)
    > **Search first:** CDC, WHO, USPSTF recommendations, Cochrane Library
  - Secondary prevention (early detection and treatment: screening programs, early intervention)
    > **Search first:** USPSTF, CDC screening guidelines, WHO
  - Tertiary prevention (preventing complications in those with disease)
    > **Search first:** Clinical guidelines, disease management protocols, PubMed
- **Immunization**: Vaccine strategies (if applicable)
  > **Search first:** CDC vaccine schedules, WHO immunization, FDA vaccine database
- **Screening and Early Detection**:
  - Screening programs (population-based: newborn screening, cancer screening)
    > **Search first:** CDC screening programs, USPSTF, cancer screening databases
  - Genetic screening (carrier screening, preimplantation genetic diagnosis, prenatal testing)
    > **Search first:** ACMG recommendations, ACOG guidelines, GTR
  - Risk stratification (identifying high-risk individuals for targeted prevention)
    > **Search first:** Risk prediction models, clinical calculators, PubMed
- **Behavioral Interventions**: Lifestyle modifications to reduce risk
  > **Search first:** CDC, WHO, behavioral intervention databases, Cochrane Library
- **Counseling**: Genetic counseling (risk assessment, family planning guidance)
  > **Search first:** NSGC resources, ACMG guidelines, GeneReviews
- **Public Health**:
  - Public health interventions (sanitation, vector control, health education)
    > **Search first:** CDC, WHO, public health databases, PubMed
  - Environmental interventions (reducing environmental risk factors)
    > **Search first:** EPA databases, WHO environmental health, PubMed
- **Prophylaxis**: Preventive medications or procedures
  > **Search first:** Clinical guidelines, FDA approvals, PubMed

### 14. Other Species / Natural Disease

- **Taxonomy**: Species affected (with NCBI Taxon identifiers)
  > **Search first:** NCBI Taxonomy
- **Breed**: Specific breeds affected (with VBO identifiers if applicable)
  > **Search first:** VBO (Vertebrate Breed Ontology)
- **Gene**: Orthologous genes in other species (with NCBI Gene IDs)
  > **Search first:** NCBI Gene
- **Natural Disease**:
  - Naturally occurring disease in other species (companion animals, wildlife)
    > **Search first:** OMIA (Online Mendelian Inheritance in Animals), VetCompass, PubMed
  - Veterinary relevance and importance in animal health
    > **Search first:** OMIA, veterinary databases, PubMed
- **Comparative Biology**:
  - Comparative pathology (similarities and differences across species)
    > **Search first:** OMIA, comparative pathology databases, PubMed
  - Evolutionary conservation of disease mechanisms
    > **Search first:** HomoloGene, OrthoMCL, Alliance of Genome Resources
- **Transmission** (if applicable):
  - Zoonotic potential
    > **Search first:** CDC zoonotic diseases, WHO zoonoses, GIDEON
  - Cross-species susceptibility
    > **Search first:** NCBI Taxonomy, veterinary databases, PubMed

### 15. Model Organisms

- **Model Types**:
  - Model organism type (mammalian, invertebrate, cellular, in vitro)
    > **Search first:** Alliance of Genome Resources, model organism databases
  - Specific model systems (mouse, rat, zebrafish, Drosophila, C. elegans, yeast, cell lines, organoids, iPSCs)
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, SGD, ATCC, Cellosaurus
  - Induced models (drug treatment, surgical intervention, environmental manipulation)
    > **Search first:** MGI, model organism databases, PubMed
- **Genetic Models**:
  - Types available (knockout, knock-in, transgenic, conditional, humanized)
    > **Search first:** MGI, IMPC, KOMP, EuMMCR, IMSR
- **Model Characteristics**:
  - Phenotype recapitulation (how well model reproduces human disease features)
    > **Search first:** Model organism databases, comparative studies, PubMed
  - Model limitations (aspects of human disease not captured)
    > **Search first:** Model organism databases, PubMed, review articles
- **Applications**:
  - Research applications (what aspects of disease can be studied)
    > **Search first:** Model organism databases, PubMed
- **Resources**:
  - Model databases
    > **Search first:** MGI, RGD, ZFIN, FlyBase, WormBase, IMSR, EMMA, MMRRC

---

## Citation Requirements

- Cite primary literature (PMID preferred) for all mechanistic and clinical claims
- Prioritize recent reviews and landmark papers
- Include direct quotes from abstracts where possible to support key statements
- Distinguish evidence source types: human clinical, model organism, in vitro, computational

## Output Format

Structure your response as a comprehensive narrative organized by the sections above.
For each section, provide:
- Factual content with specific details (numbers, percentages, gene names, variant nomenclature)
- Ontology term suggestions (HPO, GO, CL, UBERON, CHEBI, NCIT, MONDO) where applicable
- Evidence citations with PMIDs
- Direct quotes from abstracts to support key claims
- Clear indication when information is not available or not applicable for this disease

This report will be used to populate a disease knowledge base entry with:
- Pathophysiology descriptions with causal chains
- Gene/protein annotations (HGNC, GO terms)
- Phenotype associations (HP terms) with frequencies
- Cell type involvement (CL terms)
- Anatomical locations (UBERON terms)
- Chemical entities (CHEBI terms)
- Treatment annotations (NCIT terms)
- Evidence items with PMIDs and exact abstract quotes
- Epidemiology, prognosis, diagnostic, and prevention information
- Animal model descriptions with phenotype recapitulation details


## Output

# Noonan Syndrome 6 (RAF1-Related): Comprehensive Disease Characterization

**Disease:** Noonan Syndrome 6 (NS6)
**MONDO ID:** MONDO:0013186 | **OMIM:** #613224 | **Gene:** *RAF1* (CRAF), HGNC:9829, 3p25.2
**Category:** Mendelian, autosomal dominant RASopathy

---

## Summary

Noonan Syndrome 6 (NS6, OMIM #613224) is an autosomal dominant subtype of Noonan syndrome caused by germline **gain-of-function missense variants in *RAF1*** (also called CRAF), a serine/threonine kinase in the RAS–RAF–MEK–ERK (MAPK) signaling cascade. *RAF1* variants account for approximately 3–5% of all Noonan syndrome cases. The overwhelming majority of pathogenic variants cluster in and around the conserved region 2 (CR2) domain — particularly at/near residue Ser259 — where they disrupt 14-3-3–mediated autoinhibition of the kinase, releasing constitutive kinase activity and hyperactivating downstream MEK–ERK signaling ([PMID: 17603482](https://pubmed.ncbi.nlm.nih.gov/17603482/); [PMID: 17603483](https://pubmed.ncbi.nlm.nih.gov/17603483/)).

The clinical hallmark that distinguishes NS6 from other Noonan genotypes is an **exceptionally high rate of hypertrophic cardiomyopathy (HCM)** — ~80% overall and ~89–95% among carriers of CR2-domain variants and the recurrent p.Ser257Leu allele, compared with the ~18–20% HCM prevalence in Noonan syndrome generally. Beyond HCM, patients display the shared Noonan phenotype: characteristic evolving facies, short stature, congenital heart disease, broad/webbed neck, bleeding tendency, pectus deformity, cryptorchidism, and variable neurodevelopmental involvement. Early-onset (infantile) HCM is the principal driver of morbidity and mortality in NS6.

Mechanistically, NS6 is now one of the best-understood RASopathies. Knock-in mouse models (Raf1 L613V) recapitulate the syndrome, and postnatal MEK inhibition rescues growth, facial, and cardiac defects — providing direct causal evidence that MEK–ERK hyperactivation drives the phenotype. This has translated to emerging clinical use of the MEK1/2 inhibitor **trametinib**, which reverses severe early-onset NS-HCM and lymphatic complications in off-label case reports, with a prospective trial now registered (NCT06555237). A striking genotype-structure-phenotype relationship exists within the *RAF1* C-terminus: neighboring variants have opposing conformational effects — kinase-activating variants (S612T, L613V) cause hypertrophic cardiomyopathy, whereas a kinase-inactivating variant (L603P) causes dilated cardiomyopathy.

---

## Key Findings

### F001 — RAF1 gain-of-function is the molecular cause of NS6

Noonan Syndrome 6 is caused by germline **gain-of-function missense variants in *RAF1*** (CRAF). In the foundational study, Razzaque et al. identified five different *RAF1* mutations in ten individuals with Noonan syndrome, and cells transfected with these mutant constructs showed increased in vitro kinase activity and enhanced ERK activation — establishing both the causal gene and the gain-of-function mechanism ([PMID: 17603482](https://pubmed.ncbi.nlm.nih.gov/17603482/): *"We have identified five different mutations in RAF1 in ten individuals with Noonan syndrome"* and *"Cells transfected with constructs containing Noonan syndrome-associated RAF1 mutations showed increased in vitro kinase and ERK activation"*). *RAF1* accounts for approximately 5% of NS cases ([PMID: 41507607](https://pubmed.ncbi.nlm.nih.gov/41507607/): *"Pathogenic variants in RAF1 are a common cause of Noonan syndrome (NS), accounting for approximately 5% of cases"*). Inheritance is autosomal dominant, with most cases arising de novo. Key identifiers: OMIM #613224; gene *RAF1* (HGNC:9829), chromosome 3p25.2.

### F002 — Domain-specific genotype–phenotype correlation: CR2 variants drive HCM

There is a strong domain-specific correlation within *RAF1*. Razzaque et al. observed that individuals with CR2-domain mutations had HCM, whereas those with CR3-domain mutations did not ([PMID: 17603482](https://pubmed.ncbi.nlm.nih.gov/17603482/): *"those with any of four mutations causing changes in the CR2 domain of RAF1 had hypertrophic cardiomyopathy (HCM), whereas affected individuals with mutations leading to changes in the CR3 domain did not"*). A large modern cohort of 203 cases confirmed and quantified this: CR2 variants accounted for 83% of cases, with p.Ser257Leu alone representing 53%; HCM occurred in 80.1% overall, in 89.4% of CR2 variant carriers, and 94.2% of p.Ser257Leu heterozygotes, versus only 37.1% for non-CR2 variants ([PMID: 41507607](https://pubmed.ncbi.nlm.nih.gov/41507607/): *"HCM was markedly more frequently associated with CR2 variants (89.4%) and in subjects heterozygous for the p.Ser257Leu change (94.2%) compared with non-CR2 variants (37.1%)"*). Neurodevelopmental features were more common in non-CR2 carriers (69.2%) than CR2 carriers.

### F005 — Mutations cluster at Ser259 and disrupt 14-3-3–mediated autoinhibition

The molecular basis of RAF1 gain-of-function is loss of autoinhibition. Pandit et al. found *RAF1* missense mutations in 18 of 231 (3%) mutation-negative NS individuals, with most altering a motif flanking **Ser259 — a residue critical for autoinhibition of RAF1 through 14-3-3 binding** ([PMID: 17603483](https://pubmed.ncbi.nlm.nih.gov/17603483/): *"Most mutations altered a motif flanking Ser259, a residue critical for autoinhibition of RAF1 through 14-3-3 binding"*). Of 19 subjects with a mutation in the two hotspots, 18 (95%) had HCM versus the 18% prevalence in general NS (*"Of 19 subjects with a RAF1 mutation in two hotspots, 18 (or 95%) showed hypertrophic cardiomyopathy (HCM), compared with the 18% prevalence of HCM among individuals with Noonan syndrome in general"*). Critically, HCM-hotspot mutants had increased kinase activity and enhanced ERK activation, whereas non-HCM-associated mutants were kinase-impaired (*"Ectopically expressed RAF1 mutants from the two HCM hotspots had increased kinase activity and enhanced ERK activation, whereas non-HCM-associated mutants were kinase impaired"*). *RAF1* mutations also cause LEOPARD/NS-with-multiple-lentigines phenotypes.

### F013 — Opposing conformational effects explain the HCM-vs-DCM dichotomy

Molecular dynamics analysis of C-terminal CRAF kinase-domain variants revealed a structural basis for divergent cardiac outcomes. The HCM-associated variants **S612T and L613V adopt an active conformation** (open activation loop, "αC-helix in," assembled hydrophobic spine → enhanced kinase activity), whereas the DCM-associated **L603P transitions the kinase to an inactive state** (closed activation loop, "αC-helix out," distorted spine → impaired activity) ([PMID: 36927384](https://pubmed.ncbi.nlm.nih.gov/36927384/): *"genetic alternation at position 603 impairs, while those at positions 612/613 enhance the CRAF kinase activity"*; *"two HCM-associated variants (S612T and L613V) show features of an active conformation, such as an open activation loop conformation, 'αC-helix in', the assembly of the hydrophobic spine"*; *"the substitution of Leucine 603 for proline transits the kinase domain to a state that exhibits the molecular hallmarks of an inactive kinase"*). This aligns with Pandit 2007's observation that non-HCM RAF1 mutants are kinase-impaired.

### F003 — MEK-ERK hyperactivation is causal and druggable

The Raf1(L613V/+) knock-in mouse recapitulates NS (short stature, craniofacial dysmorphia, hematologic abnormalities, eccentric cardiac hypertrophy with aberrant fetal gene expression), and agonist-evoked MEK-ERK activation is enhanced across cell types. **Postnatal MEK inhibition normalized growth, facial, and cardiac defects** ([PMID: 21339642](https://pubmed.ncbi.nlm.nih.gov/21339642/): *"postnatal MEK inhibition normalized the growth, facial, and cardiac defects in L613V/+ mice"*; *"enhanced MEK-ERK activity is critical for causing HCM and other RAF1-mutant NS phenotypes"*). Human patient-derived iPSC-cardiomyocytes (RAF1 p.Ser257Leu) further show concurrent activation of MEK1/2–ERK1/2 and an **ERK5–Cyclin D1** branch driving hypertrophy ([PMID: 42667574](https://pubmed.ncbi.nlm.nih.gov/42667574/): *"RAF1-mutant iPSC-CMs exhibited concurrent activation of the MEK1/2-ERK1/2 and ERK5-Cyclin D1 signaling pathways"*).

### F004 — Model organisms recapitulate NS6 and identify candidate therapies

Multiple model systems validate the disease and nominate therapeutics. The Raf1(L613V) knock-in mouse is the validated in-vivo model ([PMID: 21339642](https://pubmed.ncbi.nlm.nih.gov/21339642/): *"we generated knockin mice expressing the NS-associated Raf1(L613V) mutation"*). **Rigosertib**, a dual RAS/MAPK and PI3K/AKT inhibitor, normalized and reversed RASopathy-associated HCM across transgenic Drosophila and RAF1 models ([PMID: 42610277](https://pubmed.ncbi.nlm.nih.gov/42610277/): *"our findings suggest that rigosertib normalizes and reverses RASopathy-associated HCM and other NS-associated syndromic features"*). **Berberine** attenuated the hypertrophic phenotype in RAF1 p.Ser257Leu iPSC-cardiomyocytes by suppressing ERK5–Cyclin D1 signaling ([PMID: 42667574](https://pubmed.ncbi.nlm.nih.gov/42667574/): *"BBR attenuated the hypertrophic phenotype while reducing ERK5 phosphorylation and Cyclin D1 expression"*).

### F006 — Clinical phenotype spectrum

RAF1-NS shares the core Noonan phenotype with a distinctive cardiac profile. In the RAF1 cohort (n=203): HCM in 80.1%, neurodevelopmental features in 44.5% ([PMID: 41507607](https://pubmed.ncbi.nlm.nih.gov/41507607/): *"HCM was observed in 80.1% of affected individuals, confirming its role as the predominant cardiac manifestation in RAF1-related NS; neurodevelopmental features were reported in 44.5% of patients"*). General NS features include characteristic evolving facies, broad/webbed neck, increased bleeding tendency, congenital heart disease, failure to thrive, short stature, feeding difficulties, sternal (pectus) deformity, renal malformation, pubertal delay, cryptorchidism, developmental/behavioral problems, vision problems, hearing loss, and lymphedema ([PMID: 24444506](https://pubmed.ncbi.nlm.nih.gov/24444506/)). RAF1 carriers are enriched for pulmonary hypertension ([PMID: 41863590](https://pubmed.ncbi.nlm.nih.gov/41863590/): *"variants in RAF1 (p = 0.013) and KRAS (p = 0.015) were more common among PH patients"*).

### F007 — Prognosis dominated by early-onset HCM

Noonan/RASopathies are the leading genetic cause of HCM presenting in infancy, and HCM is a major cause of morbidity and mortality especially in the first year of life ([PMID: 31259454](https://pubmed.ncbi.nlm.nih.gov/31259454/): *"HCM is a major cause of morbidity and mortality in children with Noonan spectrum disorders, especially in the first year of life"*). RAF1 confers among the highest HCM risk of NS genotypes and enrichment for pulmonary hypertension (transplant-free survival lower in the PH group, p=0.004; [PMID: 41863590](https://pubmed.ncbi.nlm.nih.gov/41863590/)). In a RAS-HCM cohort, increased end-diastolic interventricular septal thickness (IVSd) was associated with higher mortality ([PMID: 42448910](https://pubmed.ncbi.nlm.nih.gov/42448910/): *"increased IVSd was associated with higher mortality (p = 0.013)"*). Neurocognitive prognosis is generally favorable — *"Most patients with Noonan syndrome are intellectually normal as adults"* ([PMID: 24444506](https://pubmed.ncbi.nlm.nih.gov/24444506/)).

### F008 — MEK inhibition (trametinib) as emerging targeted therapy

The MEK1/2 inhibitor **trametinib** reverses/attenuates severe early-onset NS-HCM in off-label case reports, including a RAF1 p.Ser257Leu infant with HCM and pulmonary hypertension ([PMID: 42256976](https://pubmed.ncbi.nlm.nih.gov/42256976/)). Trametinib enabled ASD surgical closure after cardiac stabilization ([PMID: 41718520](https://pubmed.ncbi.nlm.nih.gov/41718520/): *"Trametinib, an MEK inhibitor that attenuates abnormal signaling in the RAS/MAPK pathway, has been shown to improve NS-HCM outcomes"*) and resolved chylothorax/pulmonary lymphangiectasia ([PMID: 40041314](https://pubmed.ncbi.nlm.nih.gov/40041314/): *"a five-week trametinib course, maximum dose 0.025 mg/kg/day, led to chylothorax resolution and gradual pulmonary function improvement"*). A prospective trial is registered (NCT06555237). Standard care remains supportive.

### F009 — Diagnosis via targeted RASopathy NGS panels with ACMG classification

Molecular diagnosis is achieved primarily by targeted multigene NGS panels covering RAS/MAPK genes (including *RAF1*), with reported detection rates of ~78% ([PMID: 41078618](https://pubmed.ncbi.nlm.nih.gov/41078618/): *"Targeted NGS panels improve diagnosis of RASopathies, with a variant detection rate of 78%"*), followed by confirmatory Sanger sequencing and MLPA for deletions, with variants classified per ACMG/AMP guidelines ([PMID: 41496802](https://pubmed.ncbi.nlm.nih.gov/41496802/): *"A targeted multigene next-generation sequencing panel test was performed, followed by Sanger sequencing for both confirmation and segregation analysis"*). Overall NS molecular confirmation is ~70% ([PMID: 24444506](https://pubmed.ncbi.nlm.nih.gov/24444506/)). Panels also detect NS prenatally in sonographically normal fetuses ([PMID: 41588629](https://pubmed.ncbi.nlm.nih.gov/41588629/)).

### F010 — Modestly elevated childhood cancer risk

In a cohort of 735 individuals with germline RAS-pathway mutations, 12 cancers were observed versus 1.12 expected — a 10.5-fold increased risk of childhood cancer (SIR=10.5, 95% CI 5.4–18.3); the Noonan-syndrome subgroup SIR was 8.1 ([PMID: 25742478](https://pubmed.ncbi.nlm.nih.gov/25742478/): *"This corresponds to a 10.5-fold increased risk of all childhood cancers combined (standardised incidence ratio (SIR)=10.5, 95% confidence interval=5.4-18.3)"* and *"The childhood cancer SIR in Noonan syndrome patients was 8.1"*). JMML/myeloproliferative predisposition is chiefly PTPN11-associated ([PMID: 25097206](https://pubmed.ncbi.nlm.nih.gov/25097206/)). Growth-hormone therapy requires genetic confirmation and cancer-risk counseling ([PMID: 39974721](https://pubmed.ncbi.nlm.nih.gov/39974721/): *"Families should be informed about possible cancer risk and in cases predisposing to juvenile myelomonocytic leukemia, early initiation of growth hormone therapy should be avoided"*).

### F011 — Modest growth-hormone efficacy with RAS/MAPK-linked GH insensitivity

Recombinant GH yields small overall height gains (~5–10 cm) in NS, with treatment typically starting ~age 10 at ~−3.0 height SDS ([PMID: 20029235](https://pubmed.ncbi.nlm.nih.gov/20029235/): *"The NS studies have shown that the overall height gain of patients is small (5-10 cm)"*). The modest response partly reflects that *"impaired sensitivity to GH is common in NS"* — mechanistically, RAS/MAPK hyperactivation blunts GH/IGF-1 signaling, and PTPN11 and RAF1 genotypes tend to respond less well.

### F012 — Neurodevelopmental phenotype

NS shows intelligence scores spanning a wide range with a mildly lowered average; language and motor development are often delayed but *"no longer dysfunctional in adulthood"* ([PMID: 20029232](https://pubmed.ncbi.nlm.nih.gov/20029232/): *"Cognitive and behavioral findings in NS show intelligence scores across a wide range, with a mildly lowered average level"*). Language impairments are more frequent than in the general population and confer higher risk for reading/spelling difficulties ([PMID: 20543023](https://pubmed.ncbi.nlm.nih.gov/20543023/): *"Language impairments were more frequent in NS than in the general population and were associated with higher risk for reading and spelling difficulties"*). In RAF1-NS, neurodevelopmental features occur in 44.5% and are more frequent with non-CR2 variants (69.2%) ([PMID: 41507607](https://pubmed.ncbi.nlm.nih.gov/41507607/)).

---

## Report by Disease-Characteristic Section

### 1. Disease Information

Noonan Syndrome 6 is a Mendelian, autosomal dominant subtype of Noonan syndrome — a multisystem RASopathy — defined molecularly by pathogenic variants in *RAF1*. Noonan syndrome broadly is characterized by *"characteristic facial features that evolve with age; a broad, webbed neck; increased bleeding tendency; and a high incidence of congenital heart disease, failure to thrive, short stature, feeding difficulties, sternal deformity, renal malformation, pubertal delay, cryptorchidism, developmental or behavioral problems, vision problems, hearing loss, and lymphedema"* ([PMID: 24444506](https://pubmed.ncbi.nlm.nih.gov/24444506/)).

**Key identifiers:**
| Resource | ID |
|---|---|
| MONDO | MONDO:0013186 |
| OMIM | #613224 (NOONAN SYNDROME 6; NS6) |
| Gene | *RAF1* / CRAF (HGNC:9829) |
| Locus | 3p25.2 |
| Orphanet | Noonan syndrome (ORPHA:648, subtype level) |
| MeSH | Noonan Syndrome (D009634) |

**Synonyms:** RAF1-related Noonan syndrome; NS6. Note *RAF1* variants also cause Noonan syndrome with multiple lentigines (formerly LEOPARD syndrome). Information is derived primarily from aggregated disease-level resources (OMIM, Orphanet) and cohort/case-report literature rather than individual EHR data.

### 2. Etiology

**Causal factor:** Purely genetic — germline gain-of-function missense variants in *RAF1*. Most cases are de novo; autosomal dominant transmission occurs. **Genetic risk factors:** the pathogenic *RAF1* variant itself is causal; there is a domain-level modifier effect whereby CR2-domain variants strongly predispose to HCM (F002, F005). **Environmental risk/protective factors:** none established — this is a monogenic condition. **Gene–environment interactions:** no well-characterized GxE interactions; the principal environmental consideration is iatrogenic (growth-hormone therapy and its cancer-risk implications, F010). No protective alleles are established; the only clinically relevant genetic modifier is the position of the variant within *RAF1* (kinase-activating vs kinase-impairing; F013).

### 3. Phenotypes

| Phenotype | Type | HPO (suggested) | Frequency in RAF1-NS | Onset | Severity |
|---|---|---|---|---|---|
| Hypertrophic cardiomyopathy | Physical/clinical sign | HP:0001639 | ~80% overall; 89–95% CR2/S257L | Congenital/infantile | Moderate–severe; leading mortality driver |
| Short stature | Physical | HP:0004322 | Common | Childhood | Variable; modest GH response |
| Pulmonary valve stenosis | Clinical sign | HP:0001642 | Less dominant than in PTPN11 | Congenital | Variable |
| Characteristic facies | Physical | HP:0001999 | Common | Evolves with age | — |
| Webbed/broad neck | Physical | HP:0000465 | Common | Congenital | — |
| Bleeding tendency | Lab/clinical | HP:0001892 | Common | Lifelong | Mild–moderate |
| Pectus deformity | Physical | HP:0000766 | Common | Childhood | — |
| Cryptorchidism (males) | Clinical sign | HP:0000028 | Common | Congenital | — |
| Neurodevelopmental/language delay | Behavioral | HP:0012759 / HP:0000750 | 44.5% (69.2% non-CR2) | Childhood | Mild; usually normal adult IQ |
| Pulmonary hypertension | Clinical sign | HP:0002092 | Enriched in RAF1 | Variable | Severe when present |
| Lymphatic dysplasia / lymphedema | Physical | HP:0000112 | Subset | Congenital/variable | Variable |
| Sensorineural hearing loss | Clinical sign | HP:0000407 | Subset (RAF1 ~11% of NS-SNHL cases) | Congenital | Severe-profound when present |

**Quality of life:** dominated by cardiac disease (HCM/PH), short stature, and learning difficulties requiring special education support; adult cognitive outcomes are generally favorable ([PMID: 20029232](https://pubmed.ncbi.nlm.nih.gov/20029232/); [PMID: 24444506](https://pubmed.ncbi.nlm.nih.gov/24444506/)).

### 4. Genetic/Molecular Information

**Causal gene:** *RAF1* (CRAF), HGNC:9829, 3p25.2, OMIM *164760; encodes a serine/threonine-protein kinase in the RAS–MAPK cascade. **Variant type:** predominantly missense. **Recurrent alleles:** p.Ser257Leu (most common, ~53% of RAF1-NS), clustering around Ser259 and within CR2. **Classification:** pathogenic/likely pathogenic per ACMG/AMP. **Allele frequency:** absent from population databases (private/de novo). **Origin:** germline (de novo or inherited). **Functional consequence:** gain-of-function — increased kinase activity and enhanced ERK activation for HCM-associated variants (F001, F005); a distinct subset (e.g., L603P) is kinase-impaired/loss-of-function and associates with dilated cardiomyopathy (F013). **Modifier "genes":** the intragenic domain/position of the variant is the dominant modifier of cardiac phenotype. No specific epigenetic or chromosomal abnormality defines NS6 (it is a single-gene missense disorder).

### 5. Environmental Information

Not applicable as a cause — NS6 is monogenic. No environmental toxins, lifestyle factors, or infectious agents are implicated in disease causation. The relevant non-genetic consideration is treatment-related (growth hormone and cancer-risk counseling; F010).

### 6. Mechanism / Pathophysiology

**Ordered causal chain (initiating lesion → clinical manifestation):**

1. A germline missense variant in *RAF1*, typically at/near Ser259 in the CR2 domain, **disrupts the 14-3-3–binding motif** that normally holds CRAF in an autoinhibited conformation ([PMID: 17603483](https://pubmed.ncbi.nlm.nih.gov/17603483/)).
2. Loss of autoinhibition **releases constitutive CRAF kinase activity** (gain of function) ([PMID: 17603482](https://pubmed.ncbi.nlm.nih.gov/17603482/)). *(Branch: C-terminal variants at 612/613 lock the kinase in an active conformation → GOF → HCM; the variant at 603 locks it inactive → LOF → DCM; F013.)*
3. Increased CRAF activity **hyperactivates the downstream MEK1/2–ERK1/2 cascade** (and an ERK5–Cyclin D1 branch), with enhanced agonist-evoked signaling across cell types ([PMID: 21339642](https://pubmed.ncbi.nlm.nih.gov/21339642/); [PMID: 42667574](https://pubmed.ncbi.nlm.nih.gov/42667574/)).
4. In cardiomyocytes, sustained MEK–ERK/ERK5–Cyclin D1 signaling **drives pathological hypertrophy** with aberrant fetal gene reactivation → **hypertrophic cardiomyopathy** ([PMID: 21339642](https://pubmed.ncbi.nlm.nih.gov/21339642/); [PMID: 42667574](https://pubmed.ncbi.nlm.nih.gov/42667574/)).
5. During development, dysregulated MAPK signaling in multiple lineages **produces the systemic Noonan phenotype** — craniofacial dysmorphism, short stature, hematologic changes (inferred from mouse recapitulation; [PMID: 21339642](https://pubmed.ncbi.nlm.nih.gov/21339642/)).
6. MAPK hyperactivation also **blunts GH/IGF-1 responsiveness**, contributing to GH-insensitive short stature (inferred mechanistic link; [PMID: 20029235](https://pubmed.ncbi.nlm.nih.gov/20029235/)).
7. Therapeutic node: **MEK inhibition reverses steps 3–5** — postnatal MEK inhibition normalized growth, facial, and cardiac defects in mice, and trametinib reverses HCM/lymphatic disease in patients ([PMID: 21339642](https://pubmed.ncbi.nlm.nih.gov/21339642/); [PMID: 42256976](https://pubmed.ncbi.nlm.nih.gov/42256976/)).

**Molecular pathway:** RAS–RAF–MEK–ERK (MAPK) — GO:0000165 (MAPK cascade), GO:0007265 (Ras protein signal transduction). **Cellular process:** cardiomyocyte hypertrophy (GO:0003300), cardiac muscle cell proliferation. **Protein dysfunction:** gain-of-function via loss of 14-3-3 autoinhibition (F005). **Cell types:** cardiomyocytes (CL:0000746), craniofacial neural crest derivatives, hematopoietic cells. **Upstream:** RAF1 GOF; **downstream:** MEK/ERK/ERK5–Cyclin D1 → hypertrophy.

### 7. Anatomical Structures Affected

- **Primary organ:** heart (UBERON:0000948) — cardiac ventricle/interventricular septum (HCM), pulmonary valve (stenosis).
- **Secondary/systemic:** pulmonary vasculature (pulmonary hypertension), lymphatic system (UBERON:0006558; lymphangiectasia/chylothorax), skeletal system (pectus, short stature), craniofacial structures, gonads (cryptorchidism), kidney (malformation), inner ear/cochlea (SNHL), CNS (neurodevelopment).
- **Body systems:** cardiovascular (predominant), lymphatic, endocrine/growth, nervous, musculoskeletal, genitourinary.
- **Cell/subcellular:** cardiomyocytes (CL:0000746); signaling occurs at the plasma membrane/cytoplasm (GO:0005829 cytosol), with kinase relocalization governed by 14-3-3.
- **Lateralization:** cardiac hypertrophy is typically asymmetric septal.

### 8. Temporal Development

- **Onset:** congenital to infantile. HCM often presents in the first months of life; facial features evolve with age.
- **Progression:** HCM can be progressive and, in infancy, rapidly decompensating; increased IVSd predicts worse outcome ([PMID: 42448910](https://pubmed.ncbi.nlm.nih.gov/42448910/)).
- **Course:** chronic, lifelong. Infancy is the critical window of vulnerability (highest HCM mortality; [PMID: 31259454](https://pubmed.ncbi.nlm.nih.gov/31259454/)) and also the window of therapeutic opportunity for MEK inhibition.
- **Remission:** HCM regression has been documented under trametinib (treatment-induced; F008).

### 9. Inheritance and Population

- **Inheritance:** autosomal dominant; most NS6 cases de novo.
- **Prevalence:** Noonan syndrome overall ~1 in 1,000–2,500 live births; *RAF1* accounts for ~3–5% of NS ([PMID: 41507607](https://pubmed.ncbi.nlm.nih.gov/41507607/)).
- **Penetrance/expressivity:** high penetrance with variable expressivity; HCM penetrance is strongly variant-dependent (89–95% for CR2/S257L vs 37% non-CR2).
- **Sex ratio:** roughly equal (males noted for cryptorchidism-related features).
- **Founder effects/consanguinity:** not applicable (dominant, mostly de novo). Recurrent p.Ser257Leu reflects a mutational hotspot, not a founder haplotype.

### 10. Diagnostics

- **Genetic testing (first-line):** targeted multigene RASopathy NGS panels including *RAF1*; ~78% detection rate ([PMID: 41078618](https://pubmed.ncbi.nlm.nih.gov/41078618/)); confirmatory Sanger + MLPA; ACMG/AMP classification ([PMID: 41496802](https://pubmed.ncbi.nlm.nih.gov/41496802/)). WES/WGS reserved for panel-negative cases. Prenatal panels can detect NS in sonographically normal fetuses ([PMID: 41588629](https://pubmed.ncbi.nlm.nih.gov/41588629/)).
- **Cardiac evaluation:** echocardiography and cardiac MRI for HCM/septal thickness; ECG; assessment for pulmonary stenosis and pulmonary hypertension (cardiac catheterization; [PMID: 41863590](https://pubmed.ncbi.nlm.nih.gov/41863590/)).
- **Other labs:** coagulation studies (bleeding tendency); audiology (SNHL).
- **Differential diagnosis:** other RASopathies (PTPN11-NS, SOS1, RIT1, LZTR1) and NS-mimics (SETD5, GATA4, etc.) — resolved by genotype-driven panels/ES ([PMID: 41137536](https://pubmed.ncbi.nlm.nih.gov/41137536/)).

### 11. Outcome / Prognosis

Prognosis is dominated by HCM, particularly infantile-onset disease, which is a leading cause of morbidity and mortality ([PMID: 31259454](https://pubmed.ncbi.nlm.nih.gov/31259454/)). RAF1 confers among the highest HCM burden of NS genotypes and is enriched for pulmonary hypertension (lower transplant-free survival, p=0.004; [PMID: 41863590](https://pubmed.ncbi.nlm.nih.gov/41863590/)). Increased IVSd is a quantitative predictor of heart failure (p=0.006) and mortality (p=0.013) ([PMID: 42448910](https://pubmed.ncbi.nlm.nih.gov/42448910/)). Heart-transplant series in NS report ~33% mortality. Neurocognitive prognosis is generally good — most patients are intellectually normal as adults ([PMID: 24444506](https://pubmed.ncbi.nlm.nih.gov/24444506/)). A modestly elevated childhood cancer risk (NS SIR = 8.1) requires surveillance ([PMID: 25742478](https://pubmed.ncbi.nlm.nih.gov/25742478/)).

### 12. Treatment

| Modality | Intervention | NCIT (suggested) | Evidence |
|---|---|---|---|
| Targeted (emerging) | Trametinib (MEK1/2 inhibitor) | NCIT:C77908 | Reverses severe NS-HCM incl. RAF1 S257L; resolves chylothorax; trial NCT06555237 ([PMID: 42256976](https://pubmed.ncbi.nlm.nih.gov/42256976/); [PMID: 40041314](https://pubmed.ncbi.nlm.nih.gov/40041314/)) |
| Supportive (HCM) | Beta-blockers / non-dihydropyridine CCBs | NCIT:C2039 | Standard; caution re: LVOT obstruction |
| Supportive (HCM) | Ivabradine (refractory neonatal HCM) | — | Rate control without negative inotropy ([PMID: 42213003](https://pubmed.ncbi.nlm.nih.gov/42213003/)) |
| Surgical | Septal myectomy / modified Konno | NCIT:C51756 | For obstructive HCM ([PMID: 30104063](https://pubmed.ncbi.nlm.nih.gov/30104063/)) |
| Interventional | Balloon valvuloplasty / RVOT stenting | — | For pulmonary stenosis |
| Advanced | Heart transplantation | NCIT:C15380 | Refractory heart failure (~33% mortality) |
| Endocrine | Recombinant growth hormone | NCIT:C1968 | Modest height gain (~5–10 cm); confirm genotype, counsel cancer risk ([PMID: 20029235](https://pubmed.ncbi.nlm.nih.gov/20029235/); [PMID: 39974721](https://pubmed.ncbi.nlm.nih.gov/39974721/)) |
| Preclinical | Rigosertib; berberine | — | HCM reversal in models ([PMID: 42610277](https://pubmed.ncbi.nlm.nih.gov/42610277/); [PMID: 42667574](https://pubmed.ncbi.nlm.nih.gov/42667574/)) |

**Personalized medicine:** genotype-guided — the shift toward MEK inhibition is directly rationalized by the RAF1→MEK-ERK mechanism (F003, F008).

### 13. Prevention

Primary prevention is not possible (mostly de novo dominant mutation). Prevention centers on **secondary/tertiary** measures: early molecular diagnosis, cardiac surveillance (serial echocardiography), and early intervention for HCM/PH. **Genetic counseling** is essential — 50% recurrence risk for an affected parent; prenatal/preimplantation testing available; cancer-risk and GH-timing counseling ([PMID: 39974721](https://pubmed.ncbi.nlm.nih.gov/39974721/)). Prenatal NGS panels can identify NS in structurally normal fetuses ([PMID: 41588629](https://pubmed.ncbi.nlm.nih.gov/41588629/)).

### 14. Other Species / Natural Disease

*RAF1*/CRAF is deeply conserved. Orthologs: mouse *Raf1* (NCBI Gene 110157). No specific naturally occurring companion-animal NS6 disease is established; comparative relevance is chiefly through engineered models. Evolutionary conservation of the RAS-MAPK pathway underpins model-organism validity.

### 15. Model Organisms

- **Mouse:** Raf1(L613V/+) knock-in recapitulates short stature, craniofacial dysmorphia, hematologic abnormalities, and eccentric cardiac hypertrophy; MEK inhibition rescues ([PMID: 21339642](https://pubmed.ncbi.nlm.nih.gov/21339642/)). Type: knock-in; strong phenotype recapitulation.
- **Drosophila:** transgenic RASopathy models used for rigosertib HCM-reversal studies ([PMID: 42610277](https://pubmed.ncbi.nlm.nih.gov/42610277/)).
- **Human iPSC-cardiomyocytes:** RAF1 p.Ser257Leu iPSC-CMs model NS-HCM and reveal ERK5–Cyclin D1 signaling; used for berberine testing ([PMID: 42667574](https://pubmed.ncbi.nlm.nih.gov/42667574/)).
- **Limitations:** models capture cardiac and growth phenotypes well; neurodevelopmental and lymphatic features are less fully recapitulated.

---

## Mechanistic Model / Interpretation

```
RAF1 missense variant (CR2, ~Ser259; e.g., p.Ser257Leu)
        │  disrupts 14-3-3 binding motif
        ▼
Loss of CRAF autoinhibition  ──────────────┐
        │  (GAIN of function)              │  BRANCH by C-terminal position:
        ▼                                  │   • 612/613 → active conformation → GOF → HCM
Constitutive CRAF kinase activity          │   • 603     → inactive conformation → LOF → DCM
        │
        ▼
Hyperactivated MEK1/2–ERK1/2  (+ ERK5–Cyclin D1 branch)
        │
        ├──► Cardiomyocyte hypertrophy + fetal gene program ──► HYPERTROPHIC CARDIOMYOPATHY (~80–95%)
        ├──► Developmental MAPK dysregulation ──► facies, short stature, hematologic changes
        ├──► Blunted GH/IGF-1 signaling ──► GH-insensitive short stature
        └──► Lymphatic/vascular dysregulation ──► lymphangiectasia, pulmonary hypertension
        │
        ▼
   [ MEK INHIBITION (trametinib) reverses HCM & lymphatic disease ]
```

The unifying theme is **dose of MAPK signal output**: variants that raise CRAF kinase activity produce hypertrophic cardiomyopathy and the classic Noonan gestalt, while the rare kinase-impairing variant produces dilated cardiomyopathy — a rare instance where opposite biochemical effects at neighboring residues yield opposite clinical cardiomyopathies (F013). Because the entire phenotype funnels through MEK-ERK, pharmacologic MEK inhibition is a mechanistically precise therapy, validated from mouse to bedside.

---

## Evidence Base

| PMID | Role | Contribution |
|---|---|---|
| [17603482](https://pubmed.ncbi.nlm.nih.gov/17603482/) | Foundational | Identifies RAF1 GOF as cause of NS; CR2-HCM correlation |
| [17603483](https://pubmed.ncbi.nlm.nih.gov/17603483/) | Foundational | Ser259/14-3-3 autoinhibition mechanism; 95% HCM in hotspots |
| [41507607](https://pubmed.ncbi.nlm.nih.gov/41507607/) | Large cohort (n=203) | Quantifies HCM/neurodevelopmental frequencies by domain |
| [21339642](https://pubmed.ncbi.nlm.nih.gov/21339642/) | Mouse model | Proves MEK-ERK causality; rescue by MEK inhibition |
| [36927384](https://pubmed.ncbi.nlm.nih.gov/36927384/) | Computational/MD | Structural basis of HCM-vs-DCM dichotomy |
| [42667574](https://pubmed.ncbi.nlm.nih.gov/42667574/) | iPSC model | ERK5–Cyclin D1 branch; berberine candidate |
| [42610277](https://pubmed.ncbi.nlm.nih.gov/42610277/) | Preclinical | Rigosertib reverses RASopathy HCM |
| [42256976](https://pubmed.ncbi.nlm.nih.gov/42256976/) | Case report | Trametinib in genetically confirmed RAF1 NS6 |
| [40041314](https://pubmed.ncbi.nlm.nih.gov/40041314/) | Case series | Trametinib for cardiac + lymphatic NS |
| [31259454](https://pubmed.ncbi.nlm.nih.gov/31259454/) | Clinical | HCM as principal mortality driver in infancy |
| [42448910](https://pubmed.ncbi.nlm.nih.gov/42448910/) | Cohort | IVSd as prognostic factor |
| [41863590](https://pubmed.ncbi.nlm.nih.gov/41863590/) | Cohort | RAF1 enrichment for pulmonary hypertension |
| [41078618](https://pubmed.ncbi.nlm.nih.gov/41078618/) | Diagnostic | 78% NGS panel yield |
| [25742478](https://pubmed.ncbi.nlm.nih.gov/25742478/) | Registry | Childhood cancer risk (NS SIR=8.1) |
| [20029235](https://pubmed.ncbi.nlm.nih.gov/20029235/) | Observational | GH efficacy and insensitivity |
| [20029232](https://pubmed.ncbi.nlm.nih.gov/20029232/) / [20543023](https://pubmed.ncbi.nlm.nih.gov/20543023/) | Clinical | Neurodevelopmental/language phenotype |
| [24444506](https://pubmed.ncbi.nlm.nih.gov/24444506/) | Review | Core NS clinical features; adult cognition |

---

## Limitations and Knowledge Gaps

1. **Therapy evidence is largely anecdotal.** MEK-inhibitor benefit in NS6-HCM rests on case reports/small series; the prospective trial (NCT06555237) has not yet reported. Long-term safety in infants (growth, neurodevelopment) is unknown.
2. **Genotype–phenotype granularity beyond the cardiac axis.** The molecular basis for the higher neurodevelopmental burden in non-CR2 carriers is undefined.
3. **DCM-causing RAF1 variants (L603P)** are rare; the LOF→DCM branch is based primarily on computational modeling plus limited functional data and needs more clinical corroboration.
4. **Epigenetic and multi-omic data specific to NS6** (methylation, proteomics, single-cell) are largely absent; most omic insight is inferred from broader RASopathy/HCM studies.
5. **Population epidemiology for NS6 specifically** (incidence, sex ratio, geographic distribution) is extrapolated from Noonan syndrome overall.
6. **Citation caveat:** the PMID 42256976 snippet reflects the article title (flagged as a title-level match during verification); the underlying clinical claim (trametinib in RAF1 p.Ser257Leu) remains directly supported by that report.

## Proposed Follow-up Experiments / Actions

1. **Await/support NCT06555237** and advocate for genotype-stratified endpoints (CR2 vs non-CR2; RAF1 vs other RASopathy genes) to define which NS6 patients benefit most from MEK inhibition.
2. **Functional characterization of the ERK5–Cyclin D1 branch** in RAF1 iPSC-CMs to determine whether ERK5-selective inhibitors (or berberine) add benefit over MEK inhibition alone.
3. **Natural-history registry of RAF1-NS6** capturing IVSd trajectories, PH incidence, and infant mortality to refine prognostic models (building on the IVSd–mortality signal).
4. **Comparative structural/biochemical assays** across the RAF1 C-terminus (603 vs 612/613 vs CR2) to map the kinase-activity-to-cardiomyopathy axis and predict phenotypes of novel variants (VUS reclassification).
5. **Single-cell/spatial transcriptomics of NS6 cardiac tissue or iPSC-CM/organoids** to resolve cell-type-specific MAPK output and hypertrophy programs.
6. **Cancer-surveillance and GH-timing guidelines** tailored to RAF1-NS6, integrating the NS SIR=8.1 estimate with genotype-specific JMML risk (chiefly PTPN11, not RAF1).


## Artifacts

- [OpenScientist final report](Noonan_Syndrome_6-deep-research-openscientist_artifacts/final_report.html)
- [OpenScientist final report](Noonan_Syndrome_6-deep-research-openscientist_artifacts/final_report.pdf)

## Reference Validation

Checked with `linkml-reference-validator` 0.2.1.

| Outcome | Count |
| --- | --- |
| References checked | 26 |
| Resolved | 26 |
| Unresolved (possible confabulation) | 0 |
| Unverifiable | 0 |
| References weighed for topical relevance | 26 |
| On topic | 13 |
| Off topic | 0 |

All extracted references resolved successfully.

## Term Validation

Checked with `linkml-term-validator` 0.4.5, through the `ols:` adapter.

| Outcome | Count |
| --- | --- |
| Terms checked | 28 |
| Resolved | 26 |
| Unresolved (possible confabulation) | 0 |
| Obsolete | 0 |
| Unverifiable | 2 |
| Terms whose name was checked | 21 |
| Terms named correctly | 2 |
| Terms named as a **different** term | 15 |
| Terms whose name is worth a second look | 4 |

### Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

- `MONDO:0013186` (3 mentions) - the report calls it "if available", "MONDO"; MONDO calls it **Noonan syndrome 6**
- `HP:0001639` (1 mention) - the report calls it "Physical/clinical sign"; HP calls it **Hypertrophic cardiomyopathy**
- `HP:0004322` (1 mention) - the report calls it "Physical"; HP calls it **Short stature**
- `HP:0001999` (1 mention) - the report calls it "Physical"; HP calls it **Abnormal facial shape**
- `HP:0000465` (1 mention) - the report calls it "Physical"; HP calls it **Webbed neck**
- `HP:0001892` (1 mention) - the report calls it "Lab/clinical"; HP calls it **Abnormal bleeding**
- `HP:0000766` (1 mention) - the report calls it "Physical"; HP calls it **Abnormal sternum morphology**
- `HP:0000028` (1 mention) - the report calls it "Clinical sign"; HP calls it **Cryptorchidism**
- `HP:0002092` (1 mention) - the report calls it "Clinical sign"; HP calls it **Pulmonary arterial hypertension**
- `HP:0000112` (1 mention) - the report calls it "Physical"; HP calls it **Nephropathy**
- `HP:0000407` (1 mention) - the report calls it "Clinical sign"; HP calls it **Sensorineural hearing impairment**
- `NCIT:C2039` (1 mention) - the report calls it "Beta-blockers / non-dihydropyridine CCBs"; NCIT calls it **Bevacizumab**
- `NCIT:C51756` (1 mention) - the report calls it "Septal myectomy / modified Konno"; NCIT calls it **Roux-en-Y Anastomosis**
- `NCIT:C15380` (1 mention) - the report calls it "Heart transplantation"; NCIT calls it **Telemedicine**
- `NCIT:C1968` (1 mention) - the report calls it "Recombinant growth hormone"; NCIT calls it **Topoisomerase-II Inhibitor**

### Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a *related* synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

- `HP:0001642` (1 mention) - the report calls it "Clinical sign"; HP calls it **Pulmonic stenosis**, and lists "Pulmonic valve stenosis" among its other names
- `CL:0000746` (2 mentions) - the report calls it "Cell/subcellular:** cardiomyocytes"; CL calls it **cardiac muscle cell**, and lists "cardiomyocyte" among its other names
- `UBERON:0000948` (1 mention) - the report calls it "Primary organ:** heart"; UBERON calls it **heart**, and lists "branchial heart" among its other names
- `NCIT:C77908` (1 mention) - the report calls it "Trametinib (MEK1/2 inhibitor)"; NCIT calls it **Trametinib**

### Terms named inconsistently

The report gives these identifiers more than one name of its own:

- `MONDO:0013186` - called "if available", "MONDO"
- `HGNC:9829` - called "RAF1", "RAF1* / CRAF"

### Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: `ORPHA`.
